InVitae Corp (NVTA) Upgraded by BidaskClub to Hold
BidaskClub upgraded shares of InVitae Corp (NASDAQ:NVTA) from a sell rating to a hold rating in a report issued on Thursday.
NVTA has been the topic of a number of other reports. ValuEngine lowered shares of InVitae Corp from a sell rating to a strong sell rating in a research report on Tuesday, May 23rd. Zacks Investment Research lowered shares of InVitae Corp from a hold rating to a sell rating in a research report on Tuesday, July 18th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $12.69.
Shares of InVitae Corp (NASDAQ:NVTA) traded up 1.87% during mid-day trading on Thursday, reaching $10.34. 649,330 shares of the company were exchanged. The stock’s market capitalization is $437.53 million. InVitae Corp has a 12 month low of $5.76 and a 12 month high of $11.88. The stock has a 50 day moving average price of $9.49 and a 200-day moving average price of $9.75.
InVitae Corp (NASDAQ:NVTA) last posted its quarterly earnings data on Tuesday, May 9th. The medical research company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.04. InVitae Corp had a negative net margin of 260.48% and a negative return on equity of 119.10%. The firm had revenue of $10.34 million for the quarter, compared to analyst estimates of $10.90 million. During the same period last year, the firm posted ($0.80) EPS. InVitae Corp’s quarterly revenue was up 161.1% on a year-over-year basis. Analysts predict that InVitae Corp will post ($2.39) earnings per share for the current year.
Institutional investors have recently bought and sold shares of the stock. Donald L. Hagan LLC purchased a new position in InVitae Corp during the first quarter worth $111,000. Renaissance Technologies LLC purchased a new position in InVitae Corp during the fourth quarter worth $879,000. HighTower Advisors LLC raised its position in InVitae Corp by 11.9% in the first quarter. HighTower Advisors LLC now owns 252,744 shares of the medical research company’s stock worth $2,792,000 after buying an additional 26,787 shares during the period. State Street Corp raised its position in InVitae Corp by 9.4% in the fourth quarter. State Street Corp now owns 338,514 shares of the medical research company’s stock worth $2,688,000 after buying an additional 29,017 shares during the period. Finally, Highbridge Capital Management LLC purchased a new position in InVitae Corp during the first quarter worth $302,000.
About InVitae Corp
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.